A new Section 337 complaint involving spectral flow cytometry systems has created potential import risk for laboratories, distributors, service providers, and research institutions. Although no investigation or exclusion order currently exists, affected companies should identify supply chain exposure before the proceeding advances.
What the Cytek Section 337 Complaint Means
Cytek Biosciences, Inc. filed its complaint with the U.S. International Trade Commission on October 8, 2026. Assigned Docket No. 3943, the complaint alleges unlawful importation, sale for importation, and sale after importation of certain spectral flow cytometry systems and components.
The named respondents are Beckman Coulter, Inc. of Brea, California, and Beckman Coulter Biotechnology (Suzhou) Co., Ltd. of China. Cytek has requested a limited exclusion order, cease and desist orders, and a bond during the 60-day Presidential review period. The asserted patents, claims, and precise accused product scope were not publicly identified at the complaint-receipt stage.
A Complaint Is Not an Exclusion Order
The procedural status is critical. As of October 20, 2026, the Commission has received the complaint but has not instituted a Section 337 investigation. Receipt does not establish infringement, a statutory violation, or grounds for excluding merchandise from the United States.
If the Commission institutes an investigation, it will generally identify the intellectual property rights, claims, respondents, and scope of the investigation. The proceeding would then move through discovery, claim construction where applicable, an evidentiary hearing, and Commission review before any final remedy could issue.
The Requested Remedies Affect Admissibility, Not Duty Rates
Section 337 remedies differ fundamentally from tariffs and trade remedy duties. A limited exclusion order would generally direct U.S. Customs and Border Protection to deny entry to covered products associated with specified respondents. A cease and desist order could restrict certain domestic commercial activities involving imported inventory.
These remedies do not create an additional duty that an importer can pay to secure entry. They also do not create duty drawback eligibility. If an exclusion order eventually applies, the central issue is whether the merchandise may enter the United States at all, not whether additional customs duties are owed.
Which Supply Chains Could Face Exposure
Potentially affected organizations include research institutions, hospitals, clinical laboratories, contract research laboratories, distributors, and service providers that purchase or handle spectral flow cytometry equipment. Importers of record deserve particular attention because they are responsible for entry declarations and must respond to admissibility questions raised at the border.
The current procedural record does not establish that every Beckman Coulter flow cytometry product is within scope. Compliance teams should avoid assuming that a brand name, general product category, or country of origin conclusively determines exposure.
Build a Product and Importer Map
An effective review begins with a product-level inventory. Importers should identify system models, instrument configurations, imported modules, replacement parts, accessories, software-linked hardware, and service components connected with the named respondents. The review should capture:
- Manufacturer and supplier identity
- Country of origin and export location
- Importer of record and customs broker
- Product model, SKU, and technical description
- Harmonized Tariff Schedule classification
- Entry numbers and expected shipment dates
- Installed base and available spare parts
- Service, warranty, and maintenance obligations
Technical and legal teams should coordinate closely. Customs descriptions and tariff classifications may be too broad to determine whether a particular instrument falls within a future exclusion order. Product architecture, component functionality, patent claims, and Commission-defined scope may ultimately control.
Assess Operational Consequences Before a Remedy Exists
Organizations should evaluate how delayed or denied imports would affect instrument installations, research schedules, patient-related laboratory operations, validation work, and service commitments. Even when an installed instrument is already in the United States, future access to imported replacement components may be operationally significant.
Contingency planning can include reviewing domestic inventory, alternative suppliers, substitute equipment, repair options, contractual allocation of import risk, and the feasibility of product modifications. Any substitute must satisfy technical, quality, regulatory, and procurement requirements. A nominally similar instrument may not be a practical replacement for a validated laboratory workflow.
Immediate Compliance and Filing Priorities
Companies do not need to wait for an institution decision before organizing their response. Early preparation can reduce the time required to evaluate an investigation, communicate with a customs broker, or respond to future entry questions.
Evaluate the Public Interest Comment Process
Public interest comments for Docket No. 3943 are due by close of business on October 22, 2026. These submissions are limited to five pages, including attachments. Other written submissions are due by 5:15 p.m. on the same date. Filings should use the Commission's electronic filing system and clearly reference the docket number.
Public interest analysis generally addresses how the products are used in the United States, whether exclusion could affect public health or welfare, the availability of like or directly competitive products, the ability of alternative suppliers to replace affected volume, and the likely consequences for consumers. Hospitals and laboratories should support any submission with specific operational facts rather than generalized concerns.
The complainant's reply falls three calendar days after submissions are due. Because that calculation reaches Sunday, October 25, the applicable last-day rule appears to move the deadline to Monday, October 26, 2026. Parties should independently confirm filing requirements and system availability.
Establish an Internal Section 337 Response Plan
Importers should designate owners across trade compliance, legal, procurement, engineering, service, and laboratory operations. Relevant entry records, purchase orders, bills of materials, product specifications, supplier correspondence, and service forecasts should be preserved and organized.
Customs brokers should receive precise instructions if an investigation or remedy changes entry procedures. Generic invoice descriptions such as laboratory equipment may be insufficient where admissibility depends on a product's model, configuration, manufacturer, or technical characteristics.
A disciplined monitoring plan should cover the institution decision, identification of asserted rights, procedural schedule, claim interpretations, initial determination, Commission review, and any remedial orders. Parallel court litigation between the companies may provide commercial context, but it does not replace the Commission's independent Section 337 process.
- On October 8, 2026, Cytek Biosciences, Inc. filed a Section 337 complaint (Docket No. 3943) at the U.S. International Trade Commission alleging violations in the importation, sale for importation, and post-importation sale of certain spectral flow cytometry systems and components.* Named respondents are Beckman Coulter, Inc. (Brea, CA) and Beckman Coulter Biotechnology (Suzhou) Co., Ltd. (China). Cytek requests a limited exclusion order, cease and desist orders, and a bond during the 60-day Presidential review period. The Commission published a notice of receipt on October 14, 2026 (91 FR 65257) but has not instituted an investigation. The notice does not identify the asserted patents. Public interest comments (maximum five pages) were due October 22, 2026.
- The ITC complaint reverses the parties' roles from related Delaware district court litigation (Beckman Coulter, Inc. v. Cytek Biosciences, Inc., 1:24-cv-00945), where a jury on August 21, 2026, found mixed results including a $56 million damages award against Cytek on one claim under the doctrine of equivalents.* Cytek is challenging that finding via post-trial motions. A non-final judgment issued September 15, 2026, with Cytek's opening brief in support of judgment as a matter of law or a new trial filed around October 13, 2026 (answering briefs due December 4, 2026).
- Trade publications reported the ITC filing on October 9, 2026, describing the accused products as Beckman Coulter flow cytometry devices and components typically used for research by scientists and laboratories.* A Sandler, Travis & Rosenberg trade report on October 19, 2026, listed it among recent IPR-related ITC actions. Chinese trade sites also covered the complaint on October 9, 2026. No investigation institution notice has appeared as of late October 2026 (the Commission typically decides within 30 days of filing).
- No notable practitioner discussions of the ITC complaint appeared on X in the relevant period.* Related context includes Cytek's earlier IPR petition (IPR2025-01319) challenging claims of a Beckman Coulter flow cytometer patent. Watch for public interest submissions, any Cytek reply (due around October 26, 2026), the institution decision (identifying patents and claims), and Delaware post-trial rulings.
Frequently Asked Questions
Has the ITC Opened an Investigation?
No. As of October 20, 2026, the Commission has received Cytek's complaint but has not instituted an investigation. The filing remains an allegation. Importers may continue normal operations unless another legal restriction applies, but they should monitor for an institution decision and the resulting definition of the investigated products and claims.
What Is a Limited Exclusion Order?
A limited exclusion order generally directs U.S. Customs and Border Protection to exclude covered articles imported by or for named respondents. Its practical reach depends on the Commission's wording, the products found to violate Section 337, and subsequent Customs enforcement. It is not automatically a ban on every product within a broad commercial category.
Would an Exclusion Order Create Additional Customs Duties?
No. Section 337 exclusion is an admissibility remedy rather than an additional duty assessment. Importers generally cannot resolve an exclusion issue by paying a higher tariff. Because no new duty is created, there is no Section 337 duty payment available for recovery through duty drawback.
Who Should Review Potential Exposure?
Importers of record, customs brokers, distributors, hospitals, research institutions, clinical laboratories, contract research organizations, and equipment service providers should review their exposure. The review should include complete systems and separately imported components, particularly spare parts required to maintain installed instruments or fulfill service agreements.
How Stable Software Can Help
Keep Exclusion Risk Separate From Duty Recovery
Section 337 proceedings require specialized intellectual property and import admissibility analysis. They should not be treated as duty drawback opportunities because an exclusion order bars covered entry rather than imposing a refundable duty.
Stable Software supports a separate area of import compliance through DrawbackAI. The platform is flat-license duty drawback software that U.S. customs brokers can white-label for importer clients and use to file under their own filer codes. Stable Software charges a flat software license and never takes a percentage of the refund. Customs brokers evaluating technology for legitimate duty recovery programs can learn more about Stable Software's approach for customs brokers.
Resources
| Type | Resource |
|---|---|
| Source | Primary source |
